Fondaparinux as a safe alternative for managing heparin-induced thrombocytopenia in postoperative cardiac surgery patients

Journal of Cardiothoracic and Vascular Anesthesia

Volumn 28, Issue 4, 2014, Pages 1008-1012

  Cegarra Sanmartín, Virginia ^a   González Rodríguez, Raúl ^a   Paniagua Iglesias, Pilar ^a   Santamaría Ortiz, Amparo ^a   Cueva, Luisa F ^a   Galán Serrano, Josefa ^a   Victoria Moral Garcia M ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

cardiac surgery; fondaparinux; heparin induced thrombocytopenia; HIT; HITT

Indexed keywords

BLOOD CLOTTING FACTOR 10A; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10; POLYSACCHARIDE;

ADULT; AGED; ANTICOAGULANT THERAPY; AORTA VALVE REPLACEMENT; ARTICLE; CLINICAL ARTICLE; CONTINUOUS HEMODIAFILTRATION; CONTINUOUS RENAL REPLACEMENT THERAPY; CORONARY ARTERY BYPASS GRAFT; CREATININE CLEARANCE; FEMALE; HEART SURGERY; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; KIDNEY FAILURE; LOW DRUG DOSE; LUNG LAVAGE; MALE; MITRAL ANNULOPLASTY; MITRAL VALVE REPLACEMENT; PLEURA EFFUSION; POSTOPERATIVE CARE; PRIORITY JOURNAL; THORACOCENTESIS; THROMBOCYTE COUNT; TREATMENT OUTCOME; BLOOD; BLOOD CLOTTING; CHEMICALLY INDUCED; DOSE RESPONSE; DRUG EFFECTS; FOLLOW UP; HEART DISEASES; MIDDLE AGED; POSTOPERATIVE COMPLICATION; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; THROMBOSIS;

ADULT; AGED; ANTICOAGULANTS; BLOOD COAGULATION; CARDIAC SURGICAL PROCEDURES; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR X; FEMALE; FOLLOW-UP STUDIES; HEART DISEASES; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; MIDDLE AGED; PLATELET COUNT; POLYSACCHARIDES; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT OUTCOME;

EID: 84905718957     PISSN: 10530770     EISSN: 15328422     Source Type: Journal    
DOI: 10.1053/j.jvca.2013.09.008     Document Type: Article

References (16)

1. L. Linkins, A.L. Dans, and L.K. Moores et al. Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 141 2012 e495S e530S
2. T.E. Warkentin, J.A. Sheppard, and P. Horsewood et al. Impact of the patient population on the risk of heparin-induced thrombocytopenia Blood 96 2000 1703 1708
3. M. Thielmann, M. Bunschkowski, and P. Tossios et al. Perioperative thrombocytopenia in cardiac surgical patients-incidence of heparin-induced thrombocytopenia, morbidities and mortality Eur J Cardiothorac Surg 37 2010 1391 1395
4. G.K. Lo, C.S. Sigouin, and T.E. Warkentin What is the potential for overdiagnosis of heparin-induced thrombocytopenia? Am J Hematol 82 2007 1037 1043
5. J.L. Francis A critical evaluation of assays for detecting antibodies to the heparin-PF4 complex Semin Thromb Hemost 30 2004 359 368
6. P. Savi, B.H. Chong, and A. Greinacher et al. Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: A blinded comparative multicenter study with unfractionated heparin Blood 105 2005 139 144
7. T.E. Warkentin, M. Pai, and J.I. Sheppard et al. Fondaparinux treatment of acute heparin-induced thrombocytopenia confirmed by the serotonin-release assay: A 30-month, 16-patients case series J Thromb Haemost 9 2011 2389 2396
8. B. Lobo, C. Finch, and A. Howard et al. Fondaparinux for the treatment of patients with acute heparin-induced thrombocytopenia Thromb Haemost 99 2008 208 214
9. T.E. Warkentin, B.H. Chong, and A. Greinacher Heparin-induced thrombocytopenia: Towards consensus Thromb Haemost 79 1998 1 7
10. J.P. Wester, A. Leyte, and H.M. Oudemans-van Straaten et al. Low-dose fondaparinux in suspected heparin-induced thrombocytopenia in the critically ill Neth J Med 65 2007 101 108
11. T.E. Warkentin, J.I. Sheppard, and J.C. Moore et al. Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays J Thromb Haemost 6 2008 1304 1312
12. A. Greinacher, B. Farner, and H. Kroll et al. Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients Thromb Haemost 94 2005 132 135
13. E. Grouzi, E. Kyriakou, and I. Panagou et al. Fondaparinux for the treatment of acute heparin-induced thrombocytopenia: a single-center experience Clin Appl Throm Hemost 16 2010 663 667
14. F. Pappalardo, A. Scandroglio, and G. Maj et al. Treatment of heparin-induced thrombocytopenia after cardiac surgery: Preliminary experience with fondaparinux J Thorac Cardiovasc Surg 139 2010 790 792
15. M. Haase, M. Bellomo, and J. Rocktaeschel et al. Use of fondaparinux (ARIXTRA) in a dialysis patient with symptomatic heparin-induced thrombocytopaenia type II Nephrol Dial Transplant 20 2005 444 446
16. N.R. Bijsterveld, A.H. Moons, and S.M. Boekholdt et al. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers Circulation 106 2002 2550 2554